AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company with a market capitalization of $311.86 billion, has been at the forefront of the industry with its diverse portfolio of pharmaceuticals ...
In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
If you have only $1,500 to invest, here are three healthcare stocks to buy and hold forever (listed alphabetically). AbbVie (NYSE: ABBV) could be the poster child for how to effectively navigate a ...
Pharmaceutical stocks can bring an element of safety to your portfolio. All of this equals a rather steady stream of revenue ...
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
This year the biosimilars to Stelara (ustekinumab) stand to be the stars of the biosimilars show. The FDA has approved seven ...
AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.
AbbVie will clearly fight to keep its top-selling Humira (adalimumab) anti-inflammatory drug on the market for as long as possible – but it also has one eye on a possible successor that is ...
TOKYO : Shares in Nippon Steel fell more than 1 per cent on Monday after U.S. President Joe Biden blocked its proposed $14.9 billion acquisition of U.S. Steel, dampening growth prospects for Japan ...
Its former lead drug is an anti-inflammatory injection called Humira. At recent prices, AbbVie stock offers a 3.7% yield. The company has more than quadrupled its dividend payout since spinning ...